Kynurenine Pathway in Parkinson's Disease

Medipol University

Status: Completed

Conditions: Inflammation; Periodontal Diseases

Treatments: Other: Saliva and serum sampling; Other: Saliva, serum and GCF sampling

Study type: Interventional

Funder types: Other

Identifiers

NCT07272564

1082

Details and patient eligibility

About

Parkinson's disease is a slowly progressing disease that affects the motor and non-motor functions of an individual. Periodontitis is an inflammatory chronic disease resulting in the destruction of tooth supporting structures. Inflammation has been identified as an important factor in both diseases. Given this common mechanism, the question arises as to how they may affect each other when both diseases occur together. In this study, we compared the metabolism of tryptophan, a natural amino acid of the human body, and observed whether such a process provides a biological link between periodontitis and Parkinson's disease. We extracted the saliva and blood samples of patients of Parkinson's disease and periodontitis, patients of periodontitis and healthy human beings. Comparisons between the three were made, and it was found that levels of some metabolites of tryptophan were higher in the patients of both diseases. These findings raise the possibility of a close biological connection between periodontal and brain health. Through an increased understanding of this connection in the future, new approaches for diagnosis and treatment of Parkinson's disease and periodontitis may be developed.

Full description

Saliva and serum samples were collected from 20 Stage III, Grade B periodontitis patients with PAD (Parkinson+periodontitis group) and without PAD (periodontitis group), and 20 periodontally and systemically healthy (control group). Samples were analyzed for TRP, KYN, KYN/TRP ratio, KYNA, 3OHKYN, picolinic acid (PA), and quinolinic acid (QA) by liquid chromatography-mass spectrometry. Clinical periodontal parameters [plaque index (PI), probing pocket depth (PPD), clinical attachment loss (CAL), and bleeding on probing (BOP)] were recorded.

Enrollment: 60 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• systemically healthy

  • clinical diagnosis of periodontitis
  • clinical diagnosis of periodontal health

Exclusion criteria

• history of regular use of systemic antibiotics anti-inflammatory, or antioxidant drugs (previous 3 months)

  • nonsurgical periodontal treatment (previous 6 months)
  • surgical periodontal treatment (previous 12 months)
  • presence of<10 teeth
  • current medications affecting gingival health (calcium channel blockers, phenytoin, cyclosporine, and hormone replacement therapy)
  • diabetes
  • diagnosis of rheumatoid arthritis
  • pregnancy
  • lactating
  • smoking
  • excessive alcohol consumption.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

Active Comparator

Active Comparator group

Description:

Saliva and serum collection of patients and samples molecules analysis

Treatment:

Other: Saliva and serum sampling

Experimental

Experimental group

Description:

Samples were analyzed for TRP, KYN, KYN/TRP ratio, KYNA, 3OHKYN, picolinic acid (PA), and quinolinic acid (QA) by liquid chromatography-mass spectrometry. Clinical periodontal parameters \[plaque index (PI), probing pocket depth (PPD), clinical attachment loss (CAL), and bleeding on probing (BOP)\] were recorded.

Treatment:

Other: Saliva, serum and GCF sampling